Clinical Trials Logo

Social Phobia clinical trials

View clinical trials related to Social Phobia.

Filter by:

NCT ID: NCT00397722 Completed - Social Phobia Clinical Trials

Treatment Of Patients With Social Anxiety Disorder

Start date: November 9, 2006
Phase: Phase 2
Study type: Interventional

GW876008 is a drug which may change mans reaction to stress, by decreasing the fear, physical and behavior symptoms that people with SocAD experience in social situations.

NCT ID: NCT00380731 Completed - Social Phobia Clinical Trials

Effect of Behavior Therapy on Responses to Social Stimuli in People With Social Phobia

Start date: September 2006
Phase: N/A
Study type: Interventional

This study will evaluate the effect of cognitive behavioral therapy on the brain during emotional and behavioral responses to social stimuli in people with social phobia.

NCT ID: NCT00326430 Completed - Social Phobia Clinical Trials

Residential Cognitive and Interpersonal Therapy for Social Phobia

Start date: October 2001
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is twofold: (1) to compare the effectiveness of two promising treatments for social phobia, a new cognitive therapy model (Clark & Wells, 1995; Borge et al., 2001) and interpersonal therapy (Lipsitz, Markowitz, & Cherry, 1997), adapted for inpatient groups; and (2) to study the empirical change processes in these therapies and compare them with the cognitive and interpersonal models of change.

NCT ID: NCT00318669 Completed - Social Phobia Clinical Trials

Social Anxiety Disorder Study Of Paroxetine

Start date: December 2005
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the efficacy and safety in Social Anxiety Disorder (SAD).

NCT ID: NCT00294346 Completed - Social Phobia Clinical Trials

Safety and Efficacy Study of AV608 in Subjects With Social Anxiety Disorder

Start date: February 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to look at the safety and effectiveness of an investigational drug (AV608) when used in subjects who have Social Anxiety Disorder. AV608 is an NK-1 receptor antagonist that exhibits central nervous system activity after oral administration. The study will compare AV608 to placebo (a medically inactive substance) to see if AV608 helps the symptoms of Social Anxiety Disorder. Eligible subjects will be assigned by chance to take either AV608 or placebo for 12 weeks. During the study, subjects will be asked about their overall health and mood and their Social Anxiety Disorder.

NCT ID: NCT00282828 Completed - Social Phobia Clinical Trials

Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder

Start date: March 2006
Phase: Phase 4
Study type: Interventional

This study will compare the effectiveness of either adding clonazepam or placebo to standard treatment or switching to venlafaxine in treating generalized social anxiety disorder in individuals who have not responded to treatment with sertraline.

NCT ID: NCT00264654 Completed - Social Phobia Clinical Trials

Long-term Study Of Paroxetine in Women and Men

SAD
Start date: October 2005
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the efficacy and safety in Social Anxiety Disorder (SAD)

NCT ID: NCT00246441 Completed - Clinical trials for Alcohol Use Disorder

Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism

Start date: March 2002
Phase: Phase 4
Study type: Interventional

The purpose of the study is to determine whether an SSRI, paroxetine, improves social anxiety symptoms and alcohol use in individuals who drink to cope with social anxiety disorder.

NCT ID: NCT00202709 Completed - PTSD Clinical Trials

Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder?

Start date: May 2002
Phase: N/A
Study type: Interventional

The purpose of this study is to find out if Thought Field Therapy has effect on certain anxiety disorders; agoraphobia, social phobia, and post traumatic stress disorder (PTSD).

NCT ID: NCT00191022 Completed - Social Phobia Clinical Trials

Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder

Start date: December 2004
Phase: Phase 2
Study type: Interventional

This study is a Phase 2 trial to test the efficacy of LY686017 in the treatment of Social Anxiety Disorder.